Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304163595> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4304163595 endingPage "030006052211275" @default.
- W4304163595 startingPage "030006052211275" @default.
- W4304163595 abstract "Objective Using a prospective observational design, we assessed adverse events (AEs) after COVID-19 vaccination in Japanese patients. Methods Two doses of the mRNA-1273 (SPIKEVAX®) or BNT162b2 (COMIRNATY®) vaccine were administered to participants aged 12 to 18 years, and AEs after each dose were recorded for 14 days. Data on the duration and nature (local vs. systemic) of AEs were collected using a questionnaire. Sex-based differences in AE frequency were also analyzed. Results After the first and second doses, 152 and 135 vaccinees were enrolled, respectively. After the first dose, fever (>37.1°C) occurred in 38.9% of males and 50.0% of females, whereas local pain occurred in 89.8% and 97.7% of males and females, respectively (only SPIKEVAX® was used as the first dose). After the second dose, fever (>37.1°C) occurred in 77.8% and 82.6% of males vaccinated with COMIRNATY® and SPIKEVAX®, respectively, and 82.6% of females (all received SPIKEVAX®). The local pain rates in these groups were 80.6%, 76.3%, and 100%, respectively. After the second dose, local pain, fever (>38.1°C) and headache were significantly more common in female participants, and the median symptom duration was 3 days. Conclusions AEs were more frequent after the second dose and in females." @default.
- W4304163595 created "2022-10-11" @default.
- W4304163595 creator A5010042895 @default.
- W4304163595 creator A5014643707 @default.
- W4304163595 creator A5023574384 @default.
- W4304163595 creator A5030987094 @default.
- W4304163595 creator A5048824271 @default.
- W4304163595 creator A5051979269 @default.
- W4304163595 creator A5062687488 @default.
- W4304163595 date "2022-10-01" @default.
- W4304163595 modified "2023-10-03" @default.
- W4304163595 title "Adverse events after administration of the first and second doses of messenger RNA-based COVID-19 vaccines in Japanese subjects aged 12–18 years" @default.
- W4304163595 cites W2059796825 @default.
- W4304163595 cites W2121960517 @default.
- W4304163595 cites W2162104155 @default.
- W4304163595 cites W2591717879 @default.
- W4304163595 cites W3002539152 @default.
- W4304163595 cites W3100630068 @default.
- W4304163595 cites W3111255098 @default.
- W4304163595 cites W3129250309 @default.
- W4304163595 cites W3195267856 @default.
- W4304163595 cites W3195586393 @default.
- W4304163595 cites W3196034298 @default.
- W4304163595 cites W4200168895 @default.
- W4304163595 cites W4200454749 @default.
- W4304163595 cites W4205176005 @default.
- W4304163595 cites W4210933800 @default.
- W4304163595 cites W4212842947 @default.
- W4304163595 cites W4221011258 @default.
- W4304163595 cites W4226293215 @default.
- W4304163595 doi "https://doi.org/10.1177/03000605221127518" @default.
- W4304163595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36217268" @default.
- W4304163595 hasPublicationYear "2022" @default.
- W4304163595 type Work @default.
- W4304163595 citedByCount "1" @default.
- W4304163595 countsByYear W43041635952023 @default.
- W4304163595 crossrefType "journal-article" @default.
- W4304163595 hasAuthorship W4304163595A5010042895 @default.
- W4304163595 hasAuthorship W4304163595A5014643707 @default.
- W4304163595 hasAuthorship W4304163595A5023574384 @default.
- W4304163595 hasAuthorship W4304163595A5030987094 @default.
- W4304163595 hasAuthorship W4304163595A5048824271 @default.
- W4304163595 hasAuthorship W4304163595A5051979269 @default.
- W4304163595 hasAuthorship W4304163595A5062687488 @default.
- W4304163595 hasBestOaLocation W43041635951 @default.
- W4304163595 hasConcept C126322002 @default.
- W4304163595 hasConcept C197934379 @default.
- W4304163595 hasConcept C203014093 @default.
- W4304163595 hasConcept C22070199 @default.
- W4304163595 hasConcept C23131810 @default.
- W4304163595 hasConcept C2779134260 @default.
- W4304163595 hasConcept C3008058167 @default.
- W4304163595 hasConcept C42219234 @default.
- W4304163595 hasConcept C524204448 @default.
- W4304163595 hasConcept C71924100 @default.
- W4304163595 hasConceptScore W4304163595C126322002 @default.
- W4304163595 hasConceptScore W4304163595C197934379 @default.
- W4304163595 hasConceptScore W4304163595C203014093 @default.
- W4304163595 hasConceptScore W4304163595C22070199 @default.
- W4304163595 hasConceptScore W4304163595C23131810 @default.
- W4304163595 hasConceptScore W4304163595C2779134260 @default.
- W4304163595 hasConceptScore W4304163595C3008058167 @default.
- W4304163595 hasConceptScore W4304163595C42219234 @default.
- W4304163595 hasConceptScore W4304163595C524204448 @default.
- W4304163595 hasConceptScore W4304163595C71924100 @default.
- W4304163595 hasIssue "10" @default.
- W4304163595 hasLocation W43041635951 @default.
- W4304163595 hasLocation W43041635952 @default.
- W4304163595 hasLocation W43041635953 @default.
- W4304163595 hasOpenAccess W4304163595 @default.
- W4304163595 hasPrimaryLocation W43041635951 @default.
- W4304163595 hasRelatedWork W2410078100 @default.
- W4304163595 hasRelatedWork W2765980456 @default.
- W4304163595 hasRelatedWork W2976382042 @default.
- W4304163595 hasRelatedWork W2986927582 @default.
- W4304163595 hasRelatedWork W3010379971 @default.
- W4304163595 hasRelatedWork W3181290183 @default.
- W4304163595 hasRelatedWork W3217408445 @default.
- W4304163595 hasRelatedWork W4225401219 @default.
- W4304163595 hasRelatedWork W4307171467 @default.
- W4304163595 hasRelatedWork W4383817509 @default.
- W4304163595 hasVolume "50" @default.
- W4304163595 isParatext "false" @default.
- W4304163595 isRetracted "false" @default.
- W4304163595 workType "article" @default.